Solara Active Pharma Sciences Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/srdxtthm7gh1wrtckexnbt3n.pdf

Key Takeaways


Turnaround & Financial Performance

Jitesh Devendra: "Q3 FY'23 had been a turnaround quarter for Solara, as we have achieved most of the targeted goals when we embarked on the course correction journey last year."

Vizag Ramp-Up & Regulatory Pathway

S. Hariharan: "Our immediate priority is to offset the under-recoveries at Vizag and achieve breakeven and profitable growth in the near-term."

Ibuprofen & Product Portfolio

Jitesh Devendra: "We are probably the only company outside of China who has got the Ibuprofen approval for China market."

Cost Pressures & Margin Path

Jitesh Devendra: "Our aspirations, of course, is to get to 50%. It is only about the timing as we firm up the business plans, and when do our CIP also come into play. So, we will have a better answer. But yes, the aspiration is to be at minimum 50%."

CRAMS, Filings & Growth Levers

Jitesh Devendra: "But we are going to be very cognizant in terms of how we are going to invest in the CAPEX for the future growth of Solara."

Balance Sheet & Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue run rateMaintain ₹400 crores quarterly run rate and get back to historical revenuesOngoing
Gross marginReach minimum 50%, with aspiration to return to FY21 levels of 56%Not dated (exact guidance promised next call)
US DMF filingsFile four new DMFs in Q4, totaling six for FY23Q4 FY23
Vizag EU inspectionEU inspection to enhance Ibuprofen supply capability from VizagQ4 FY23
Vizag breakevenOffset under-recoveries and achieve breakeven at VizagNear-term
Debt comfortReach nearly 3x EBITDANext financial year
Term loan repayment₹120 crores reduction per yearAnnual
Tax rateNet effective rate of 20%-22%FY24
New product pipelineEight products filedNext financial year
Cost normalizationPower charges and consumables price increases to regularizeWithin one to two quarters

Key Metrics

MetricQ3 FY23
Revenue₹401.9 cr, grew 17% sequentially
Gross margin47.3%, improved 308 bps sequentially
Operating EBITDA₹70 cr, 17.4% margin
Reported EBITDA₹51 cr, 12.7% margin, grew 70% sequentially
Base business EBITDA margin17.7%
Regulated market revenue share72%
Net current assets reduction (9M FY23)₹42 cr
Term loan outstanding₹352 cr, reduced from ₹414 cr at beginning of year
Annual term loan reduction plan₹120 cr per year
Target net debt-to-EBITDA~3x in the next financial year
Overall capacity utilization (excl. Vizag)77%
Ibuprofen utilization (Pondy facility)~90%
New US DMFs filed in Q32, one filed from Vizag
Market extensions in Q35 for 5 existing products
Total filings in Brazil4
Vizag peak sales potential₹300-400 cr at full utilization
CRAMS revenue shareSingle digit of overall company revenue
New product pipeline for next FY8 products
Net effective tax rate (FY24 outlook)20%-22%